A study to find the role of lignocaine given in intravenous route to manage the pain of fibromyalgia patients.
Phase 4
Not yet recruiting
- Conditions
- Health Condition 1: M797- Fibromyalgia
- Registration Number
- CTRI/2019/08/020614
- Lead Sponsor
- ESI Institute of Pain Management
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients suffering from fibromyalgia with Widespread Pain Index(WPI)more than 7 and Symptom Severity Index(SSS) more than 5 or WPI 4-6 and SSS more than 9
2. Duration of fibromyalgia more than 12 weeks
3. Patient taking anti-neuropathic medicine more than 4 weeks
4. Degree of pain more than 5 according to VAS
Exclusion Criteria
1. Patients with allergy to lignocaine
2. History of cardiac dysrrythmias
3. Patients with severe hepatic and renal disease
4. Patients not giving consent
5. Poorly controlled psychiatric conditions with possible secondary gain or severe comorbidity.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method